0001683168-21-003825.txt : 20210820 0001683168-21-003825.hdr.sgml : 20210820 20210820203544 ACCESSION NUMBER: 0001683168-21-003825 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210810 FILED AS OF DATE: 20210820 DATE AS OF CHANGE: 20210820 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Abecassis Michael M CENTRAL INDEX KEY: 0001879281 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40699 FILM NUMBER: 211195082 MAIL ADDRESS: STREET 1: C/O PHARMACYTE BIOTECH INC. STREET 2: 23046 AVENIDA DE LE CORLOTA CITY: LAGUNA HILLS STATE: CA ZIP: 10041-0099 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PharmaCyte Biotech, Inc. CENTRAL INDEX KEY: 0001157075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621772151 STATE OF INCORPORATION: NV FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 23046 AVENIDA DE LA CARLOTA, SUITE 600 CITY: LAGUNA HILLS STATE: CA ZIP: 92653 BUSINESS PHONE: (917) 595.2850 MAIL ADDRESS: STREET 1: 23046 AVENIDA DE LA CARLOTA, SUITE 600 CITY: LAGUNA HILLS STATE: CA ZIP: 92653 FORMER COMPANY: FORMER CONFORMED NAME: NUVILEX, INC. DATE OF NAME CHANGE: 20090324 FORMER COMPANY: FORMER CONFORMED NAME: EFOODSAFETY COM INC DATE OF NAME CHANGE: 20010808 3 1 ownership.xml X0206 3 2021-08-10 0 0001157075 PharmaCyte Biotech, Inc. PMCB 0001879281 Abecassis Michael M 23046 AVENIDA DE LA CARLOTA SUITE 600 LAGUNA HILLS CA 92653 1 0 0 0 Common Stock 1667 D Common Stock 800 I By Transplant Consulting LLC Stock Option (right to buy) 87.00 2017-07-03 2022-07-03 Common Stock 334 D Stock Option (right to buy) 87.00 2017-07-03 2022-07-03 Common Stock 800 I By Transplant Consulting LLC Stock Option (right to buy) 102.45 2018-07-01 2023-07-01 Common Stock 334 D Stock Option (right to buy) 55.50 2019-07-01 2024-07-01 Common Stock 334 D Stock Option (right to buy) 37.05 2020-07-01 2025-07-01 Common Stock 334 D Stock Option (right to buy) 16.20 2021-07-01 2026-06-30 Common Stock 334 D The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split"). The exercise price has been adjusted to reflect the Reverse Split. /s/ Michael M. Abecassis 2021-08-20